We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+20.81%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$137M
AUM Growth
+$14M
Cap. Flow
+$285M
Cap. Flow %
208.33%
Top 10 Hldgs %
53.02%
Holding
89
New
31
Increased
13
Reduced
18
Closed
23

Top Buys

1
RADX
Radiopharm Theranostics
RADX
+$272M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$4.81M
3
KZIA
Kazia Therapeutics
KZIA
+$3.92M
4
IKT icon
Inhibikase Therapeutics
IKT
+$2.57M
5
ACET icon
Adicet Bio
ACET
+$2.43M

Top Sells

1
DAWN
Day One Biopharmaceuticals
DAWN
+$3.74M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$2.6M
3
OABI icon
OmniAb
OABI
+$2.51M
4
ZVRA icon
Zevra Therapeutics
ZVRA
+$2.28M
5
SRZN icon
Surrozen
SRZN
+$2.21M

Sector Composition

1 Healthcare 92.31%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
1
Verastem
VSTM
$530M
$21.1M 15.4%
2,732,079
+62,047
+2% +$553K
ADMA icon
2
ADMA Biologics
ADMA
$2.02B
$13.5M 9.85%
740,000
+1,000
+0.1% +$16.9K
EOLS icon
3
Evolus
EOLS
$377M
$10.9M 7.92%
1,631,588
+95,197
+6% +$645K
ZVRA icon
4
Zevra Therapeutics
ZVRA
$755M
$5.1M 3.72%
569,088
-240,912
-30% -$2.28M
IKT icon
5
Inhibikase Therapeutics
IKT
$331M
$4.81M 3.51%
2,348,147
+1,613,128
+219% +$2.57M
ABEO icon
6
Abeona Therapeutics
ABEO
$399M
$3.74M 2.73%
709,505
+258,535
+57% +$1.3M
NKTR icon
7
Nektar Therapeutics
NKTR
$2.31B
$3.59M 2.62%
85,000
– –
INDV icon
8
Indivior Pharmaceuticals
INDV
$4.79B
$3.59M 2.62%
100,000
– –
CRBP icon
9
Corbus Pharmaceuticals
CRBP
$167M
$3.17M 2.32%
+389,916
New +$4.81M
KZIA
10
Kazia Therapeutics
KZIA
$152M
$3.17M 2.32%
+460,359
New +$3.92M
XOMA
11
DELISTED
Xoma
XOMA
$3.06M 2.23%
115,000
-459
-0.4% -$14.8K
VRCA icon
12
Verrica Pharmaceuticals
VRCA
$96M
$2.94M 2.15%
+353,669
New +$1.96M
HELP
13
Cybin Inc
HELP
$449M
$2.78M 2.03%
+339,902
New +$2.19M
TELA icon
14
TELA Bio
TELA
$32.7M
$2.78M 2.03%
2,352,032
+196,513
+9% +$249K
ACAD icon
15
Acadia Pharmaceuticals
ACAD
$4.38B
$2.67M 1.95%
100,000
-74,544
-43% -$1.78M
CRSP icon
16
CALL
CRISPR Therapeutics
CRSP
$4.71B
$2.62M 1.91%
+50,000
New +$2.99M
SRZN icon
17
Surrozen
SRZN
$255M
$2.57M 1.87%
113,631
-136,515
-55% -$2.21M
ARE icon
18
CALL
Alexandria Real Estate Equities
ARE
$8.75B
$2.45M 1.79%
+50,000
New +$2.94M
XFOR icon
19
X4 Pharmaceuticals
XFOR
$360M
$2.37M 1.73%
593,573
-462,765
-44% -$1.68M
RARE icon
20
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
$2.3M 1.68%
+100,000
New +$3.29M
AYTU icon
21
AYTU BioPharma
AYTU
$23.1M
$2.12M 1.54%
813,704
-78,151
-9% -$175K
NKTR icon
22
CALL
Nektar Therapeutics
NKTR
$2.31B
$2.11M 1.54%
+50,000
New +$2.8M
DAWN
23
DELISTED
Day One Biopharmaceuticals
DAWN
$1.86M 1.36%
200,000
-447,382
-69% -$3.74M
ACET icon
24
Adicet Bio
ACET
$75.9M
$1.85M 1.35%
+220,011
New +$2.43M
SPRB
25
Spruce Biosciences
SPRB
$120M
$1.72M 1.26%
+19,742
New +$2.12M
1
2 3 4

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Stonepine Capital Management held 89 positions worth $137M, up 11% from $123M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Stonepine Capital Management deployed $285M of net new capital in Q4 2025, opening 31 new positions and adding to 13 existing holdings. Its largest new stake was Radiopharm Theranostics: 51,000,000 shares worth $851K.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Day One Biopharmaceuticals, an estimated $3.74M trimmed.

  • Stonepine Capital Management's largest Q4 2025 buy was Radiopharm Theranostics: 51,000,000 shares worth $851K.
  • Stonepine Capital Management added most to Inhibikase Therapeutics in Q4 2025, an estimated $2.57M increase.
  • Stonepine Capital Management's biggest Q4 2025 reduction was Day One Biopharmaceuticals, cutting an estimated $3.74M.
  • Stonepine Capital Management fully exited Soleno Therapeutics in Q4 2025, selling an estimated $1.62M.
  • Stonepine Capital Management's ten largest holdings make up 53% of its $137M portfolio in Q4 2025.
  • Stonepine Capital Management opened 31 new positions and closed 23 in Q4 2025.
  • Stonepine Capital Management's portfolio value rose 11% quarter-over-quarter to $137M.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.